Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.46 (market cap $9.43B), while JPMorgan Diversified Return International Eqty ETF trades at $76.97. Which is the better fit depends on your goals.
| BIO | JPIN | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | — |
52-Week High | $356.25 | $77.00 |
52-Week Low | $241.71 | $64.96 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
JPIN (JPMorgan Diversified Return International Equity ETF) trades at $76.97, up 0.8% with strong technical momentum as moving averages signal bullish conditions. The ETF provides broad exposure to foreign large-cap value stocks through a smart beta approach. Recent dividend activity shows a $0.91 distribution scheduled for June 2026, while technical indicators show mixed signals with RSI in overbought territory but ADX confirming strong trend strength.
The ETF's outlook remains positive given its diversified international exposure and value orientation, though investors face currency risk and emerging market volatility. Current technical strength suggests continued upward momentum, but overbought RSI levels indicate potential near-term consolidation. The fund's systematic approach to international value investing provides defensive characteristics in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
